EDUCATIONAL COURSE ON HEART TRANSPLANTATION Oct 2026

The Goal

The goal of the heart transplantation interactive course is to provide the latest scientific and clinical knowledge on the possibilities of ECP positioning on the transplant journey and foster discussion between peers.

Agenda

Download Agenda PDF

Day 1 - 8 October 2026

18:00 – 18:15
Welcome and introduction - Prof Markus Barten & Therakos Healthcare Stakeholder Engagement Department

18:15 – 19:45
Immune monitoring strategies for predicting and preventing heart transplant rejection: from biomarkers to clinical implementation - Dr Balazs Sax

19:45 – 20:00
Interactive discussion

20:00
Dinner

Day 2 - 9 October 2026

09:15 – 09:30
Introduction to day 2 - Prof Markus Barten

09:30 – 10:15
Current short- and long-term problems after heart transplant - Prof Andreas Zuckermann

10:15 – 10:30
Coffee break

THE POTENTIAL ROLE OF ECP AFTER HEART TRANSPLANT

10:30 – 11:15
Proposed mechanism of action of ECP - Prof James Hutchinson

11:15 – 12:00
ECP positioning in the treatment algorithm - Dr Balazs Sax

12:00 – 12:30
Interactive discussion

12:30 – 13:30
Lunch

13:30 – 14:00
ECP as immunosuppressive sparing option in high-risk patients after Heart Transplant (HTX) - Prof Andreas Zuckermann

14:00 – 14:30
Cross functional approach to monitoring and follow-up of ECP patients – the Hamburg experience - Prof Markus Barten

14:30 – 14:45
Coffee break

14:45 – 15:00
ECP in Heart Transplantation – a patient perspective - Mark Kritzy (patient)

15:00 – 15:30
Patient cases journey

15:30 – 15:45
Final remarks and close - Faculty

ECP: Extracorporeal Photopheresis

For this course, participants are required to submit one patient case for discussion 15 days in
advance of the session

All speakers are subject to contract.
This is a commercial programme run by Therakos (UK) Ltd
This information is intended for healthcare professionals based in Europe and the Middle East.

Hosted by

Prof Markus Barten

Surgical Director of Heart Failure Clinic, Department of Cardiovascular Surgery, University Heart & Vascular Center Hamburg, Germany

Brought to you by the Therakos Institute

This is a commercial programme run by Therakos (UK) Ltd.

Our Centres of Excellence (CoE) Programme is for customers only. If you are interested in attending our CoE courses please contact your Sales Representative.

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

Indications

The THERAKOS™ CELLEX™ Photopheresis System is indicated for patients older than 18 years of age for the administration of photopheresis in the following:

Cutaneous T Cell Lymphoma (CTCL)
Solid Organ Transplant Rejection (SOT) (heart, lung)

The THERAKOS™ CELLEX™ Photopheresis System is indicated in patients older than 3 years of age for the management of:

Acute and Chronic Graft versus Host Disease (aGvHD, cGvHD)

Contraindications

THERAKOS^TM Photopheresis is contraindicated in:

Patients possessing a specific history of a light sensitive disease
Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm³
Patients who have coagulation disorders or who have previously had a splenectomy

Warnings and Precautions

THERAKOS^TMPhotopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure.

Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
When prescribing and administering THERAKOS Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
Treatment frequency exceeding labelling recommendations may result in anaemia.
Venous access carries a small risk of infection and pain.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS

Consult the 8-methoxypsoralen (Methoxsalen (20 micrograms / mL)) professional leaflet or the oral 8-methoxypsoralen formulation package insert before prescribing or dispensing any medication.

Warnings and Precautions

Patients exhibiting multiple basal cell carcinomas or having a history of basal cell carcinoma should be diligently observed and treated.
Methoxsalen may cause fetal harm when given to a pregnant woman. Women undergoing photopheresis should be advised to avoid becoming pregnant.
Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents.
Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic.
Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.

Refer to the package insert for methoxsalen sterile solution (20 micrograms / mL) or the oral 8-methoxypsoralen dosage formulation for a list of all warnings and precautions.

Educational Course on Heart Transplantation